EuBiologics, a Korean vaccine maker targeting the global public health market, said it opened a new office at the Cambridge Innovation Center (CIC) in Boston, one of the largest biotech clusters in the world.
South Korean biopharmaceutical firm GC Biopharma has signed a memorandum of understanding (MOU) with Eubiologics to jointly manufacture oral cholera vaccine, Euvichol.
BUFFALO, NY / ACCESSWIRE / July 14, 2023 / POP Biotechnologies (POP BIO), a Buffalo, NY-based biopharmaceutical startup, announces top line interim results of a Phase 3 clinical trial of EuCorVac-19, a COVID-19 vaccine candidate being developed by South Korean partner EuBiologics (KOSDAQ: 206650). EuCorVac-19 is a protein-based vaccine consisting of a vaccine antigen displayed on immunogenic nanoparticles, using POP BIO's spontaneous-nanoliposome antigen particle (SNAP) technology.
SEOUL, South Korea--(BUSINESS WIRE)--EuBiologics (KOSDAQ: 206650, CEO, Dr. Baik YoungOk, Mr. Seukkeun Choi), a South Korean biotech company, announced on Jan 28th that EuCorVac-19, a COVID-19 vaccine candidate developed by EuBiologics, obtained approval to conduct Phase III comparison clinical trials (Phase III IND Approval) from the Ministry of Food and Drug Safety in South Korea.
EuBiologics said it signed nan MOU with Arabio, a Saudi Arabian biotech firm, to supply its Covid-19nvaccine EuCorVac-19 and meningococcal vaccine Eu-MCV to Saudi Arabia.nn?? : KBR(http://www.koreabiomed.com)
South Korean drugmakers have begun the process to develop COVID-19 vaccines that are effective against the new omicron variant amid concerns that the highly transmissible strain may become a dominant one soon.
EuBiologics has asked for the Ministry of Food and Drug Safety’s approval on its plan to conduct a phase 3 clinical trial of its self-developed COVID-19 vaccine candidate, becoming the second Sout
Biotech company TechInvention has tied up with South Korean firm Eubiologics to bring in an oral cholera vaccine to India. The vaccine doses would be imported initially.
South Korean biopharmaceutical company EuBiologics announced Wednesday that it will commence phase two clinical trial of its COVID-19 vaccine candidate EuCOVAC-19.